Botnar Research Center advancing research into coronavirus
The Basel-based Botnar Research Center for Child Health is providing capital in the amount of 15 million Swiss francs to its four partner institutions. In this way, the University of Basel should be in a position to advance research into dealing with the coronavirus outbreak.
3D rendering of a microscopic image of the novel coronavirus SARS-CoV-2 (img: Creativeneko/123rf)
The Botnar Research Center for Child Health (BRCCH) was founded by the University of Basel and the Swiss Federal Institute of Technology in Zurich (ETH). The University Children’s Hospital Basel (UKBB) and the Swiss Tropical and Public Health Institute (Swiss TPH), which is likewise based in Basel, are also involved with the center. BRCCH is now providing its four partner institutions with 15 million Swiss francs to facilitate research into the coronavirus, as detailed in a press release issued by the University of Basel.
The funding is to be provided by the Foundation Botnar as part of a first emergency initiative organized by the BRCCH, which was opened in 2019. Within the framework of this initiative, projects “dealing with the diagnosis and human immune response to COVID-19, as well as to projects in the fields of medical interventions and disease management” are to be supported over the next two-and-a-half years.
The BRCCH initiative will focus on two objectives: first, to come up with solutions to urgent problems in the fight against the pandemic and, second, to develop long-term approaches “so that similar situations can be better managed worldwide in the future”.
Share this article
You might also be interested in
A research project is investigating the improvement in the condition of patients who have been hospitalized due to COVID-19. docdok.health based in Basel is contributing the smartphone app for the project.Read More
The Allschwil-based pharmaceutical company Idorsia receives a payment of 45 million US dollars as part of an agreement with Neurocrine Biosciences and shall also be entitled to claim milestone payments in future. Neurocrine has exercised a licensing option for a drug developed by Idorsia to treat epilepsy..Read More
Roche has received Emergency Use Authorization in the USA for an antibody test in connection with the novel coronavirus. The tests are already being distributed around the world. In May, production capacities are to already be scaled up to the high double-digit million area.Read More
Basel is valued as a location for company headquarters. In a rating from the fDi Intelligence platform of the Financial Times, Basel achieves eighth place in Europe. No other Swiss city does better.Read More
The investment and innovation promotion agency Basel Area Business & Innovation, previously known as BaselArea.swiss, can look back on a successful year in 2019. In this regard, positive developments in the healthtech sector and in Switzerland Innovation Park Basel Area stand out.Read More
The University Hospital Basel is the first Swiss hospital to have treated two Covid-19 patients with the plasma from a patient who has recovered from the virus, which means that they are receiving the appropriate antibodies. This method is a potential therapeutic option.Read More